JP7823034B2 - 虚血後の心臓リモデリングにおけるバイオマーカー及びバイオターゲットとしてのｇｄｆ３ - Google Patents

虚血後の心臓リモデリングにおけるバイオマーカー及びバイオターゲットとしてのｇｄｆ３

Info

Publication number
JP7823034B2
JP7823034B2 JP2023520305A JP2023520305A JP7823034B2 JP 7823034 B2 JP7823034 B2 JP 7823034B2 JP 2023520305 A JP2023520305 A JP 2023520305A JP 2023520305 A JP2023520305 A JP 2023520305A JP 7823034 B2 JP7823034 B2 JP 7823034B2
Authority
JP
Japan
Prior art keywords
gdf3
cardiac
risk
patient
cardiac remodeling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023520305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544387A5 (https=
JP2023544387A (ja
Inventor
ユロ，ジャン－セバスチャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Universite Paris Cite
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Universite Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Universite Paris Cite filed Critical Assistance Publique Hopitaux de Paris APHP
Publication of JP2023544387A publication Critical patent/JP2023544387A/ja
Publication of JP2023544387A5 publication Critical patent/JP2023544387A5/ja
Application granted granted Critical
Publication of JP7823034B2 publication Critical patent/JP7823034B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2023520305A 2020-10-05 2021-10-04 虚血後の心臓リモデリングにおけるバイオマーカー及びバイオターゲットとしてのｇｄｆ３ Active JP7823034B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20306156 2020-10-05
EP20306156.9 2020-10-05
PCT/EP2021/077267 WO2022073915A1 (en) 2020-10-05 2021-10-04 Gdf3 as biomarker and biotarget in post-ischemic cardiac remodeling

Publications (3)

Publication Number Publication Date
JP2023544387A JP2023544387A (ja) 2023-10-23
JP2023544387A5 JP2023544387A5 (https=) 2024-08-14
JP7823034B2 true JP7823034B2 (ja) 2026-03-03

Family

ID=72944085

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023520305A Active JP7823034B2 (ja) 2020-10-05 2021-10-04 虚血後の心臓リモデリングにおけるバイオマーカー及びバイオターゲットとしてのｇｄｆ３

Country Status (4)

Country Link
US (1) US20230375571A1 (https=)
EP (1) EP4226160A1 (https=)
JP (1) JP7823034B2 (https=)
WO (1) WO2022073915A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114859061B (zh) * 2022-05-06 2024-10-18 华中科技大学同济医学院附属协和医院 预测心梗患者有害心室重塑和免疫治疗疗效的标志物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012057613A1 (en) 2010-10-26 2012-05-03 Umc Utrecht Holding B.V. Method for preventing myocardial infarction-related complications
JP2020506944A (ja) 2017-02-06 2020-03-05 アクセルロン ファーマ， インコーポレイテッド 心不全を処置するための組成物および方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5808007A (en) * 1993-01-12 1998-09-15 The Johns Hopkins University School Of Medicine Growth differentiation factor-3
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
EP1771557B1 (en) * 2004-06-24 2014-12-31 Acceleron Pharma Inc. GDF3 Propeptides and Related Methods
US7611834B2 (en) 2005-09-30 2009-11-03 Sandia Corporation Methods and devices for protein assays
US20090082552A1 (en) 2007-09-26 2009-03-26 Magdalena Bynum Microfluidic protein assay
WO2013137715A1 (en) * 2012-03-16 2013-09-19 Umc Utrecht Holding B.V. Biomarkers for adverse cardiac remodeling
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2017189605A1 (en) * 2016-04-25 2017-11-02 Siemens Healthcare Diagnostics Inc. Diagnostic method(s) for detecting and treating post-infarct myocardium remodeling and diffuse myocardial fibrosis
EP3409778A1 (en) * 2017-05-31 2018-12-05 Medizinische Hochschule Hannover Lncrnas gadlor 1 and 2 for use in treating and preventing cardiac remodelling
JP2022512648A (ja) * 2018-10-09 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 心筋線維化の処置のためのαＶ－インテグリン（ＣＤ５１）阻害剤の使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012057613A1 (en) 2010-10-26 2012-05-03 Umc Utrecht Holding B.V. Method for preventing myocardial infarction-related complications
JP2020506944A (ja) 2017-02-06 2020-03-05 アクセルロン ファーマ， インコーポレイテッド 心不全を処置するための組成物および方法

Also Published As

Publication number Publication date
WO2022073915A1 (en) 2022-04-14
US20230375571A1 (en) 2023-11-23
EP4226160A1 (en) 2023-08-16
JP2023544387A (ja) 2023-10-23

Similar Documents

Publication Publication Date Title
WO2016172710A2 (en) Methods and reagents for determination and treatment of organotropic metastasis
US20090197794A1 (en) Methods of Diagnosing and Treating an Inflammatory Response
CN102197146B (zh) 盐皮质激素受体激活的生物标志物
US10585102B2 (en) Characterization of cancer using detection of activated leukocyte cell adhesion molecule (ALCAM) shedding
JP6535385B2 (ja) 血管疾患診断用バイオマーカー及びその用途
CN112626207B (zh) 一种用于区分非侵袭性和侵袭性无功能垂体腺瘤的基因组合
WO2025031331A1 (zh) Plekhh2在肺动脉高压诊断和治疗方面的应用
CN104619861A (zh) 作为血清和组织生化标志物的bag3
JP7823034B2 (ja) 虚血後の心臓リモデリングにおけるバイオマーカー及びバイオターゲットとしてのｇｄｆ３
CN107012256A (zh) 腹主动脉瘤诊治标志物
JP2013213774A (ja) 結核検査用バイオマーカー
CN116270710B (zh) circRBM33作为靶点在前列腺癌诊断和治疗中的应用
KR20200058299A (ko) 갑상선암 예후 예측용 바이오 마커
CN111630185A (zh) 包含pmvk作为活性成分的用于诊断耐放射癌症或预测放射疗法预后的生物标志物组合物
JP2014095643A (ja) 炎症性疾患治療薬のスクリーニング方法、並びに炎症性疾患の治療及び検査
KR101611004B1 (ko) ＴｒｋＡ를 이용한 백혈병 진단용 조성물
CN107012257A (zh) 用于诊治腹主动脉瘤的生物标志物
US10316319B2 (en) Composition for diagnosis of liver metastasis of colorectal cancer and the use thereof
US20260000742A1 (en) THERAPEUTIC OR PREVENTIVE AGENT FOR MYOCARDIAL INFARCTION, CARDIAC FIBROSIS, OR HEART FAILURE USING Htra3 AS THERAPEUTIC TARGET
KR102337947B1 (ko) 신장암 환자의 예후 예측을 위한 limk2의 용도
Qi et al. Insulin resistance and SIK1 hyperactivation: implications for vascular remodeling in recurrent pregnancy loss
Jiang et al. MELTF-AS1 Regulates DUSP5 and Trophoblast Function via EZH2 to Inhibit Preeclampsia
Masurkar et al. The novel cardiokine GDF3 predicts adverse fibrotic remodeling post-myocardial infarction
WO2015133771A1 (ko) 신규 신경교종의 바이오마커 및 그의 용도
JP2017032588A (ja) 結核検査用バイオマーカー

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260218

R150 Certificate of patent or registration of utility model

Ref document number: 7823034

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150